Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic, uncomplicated Plasmodium falciparum infection~* Positive malaria microscopy or malaria RDT (pLDH)~* Age: 18-50 years~* Provide written informed consent~* Agree to be able to travel to clinic on days: 1, 2, 7, 10, 14, 21, and 28~Exclusion Criteria:~* Signs or symptoms of severe malaria~* Unable to provide written informed consent~* For women: pregnancy or lactation~* Hypersensitivity to ivermectin or DP~* QTc \>460 ms on ECG~* Body Mass Index (BMI) below 16 or above 32 kg/m2~* Haemoglobin concentration below 9 g/dL~* Taken ivermectin in the last month~* Taken dihydroartemisinin-piperaquine in the last 12 weeks~* Loa loa as assessed by travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan~* History and/or symptoms indicating chronic illness~* Current use of tuberculosis or anti-retroviral medication~* Previously enrolled in the same study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
- ivermectin 300 mcg/kg (Type: EXPERIMENTAL): Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
- ivermectin 600 mcg/kg (Type: EXPERIMENTAL): Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).